Our recently published nationwide Danish study was designed to address a question that urologists face regularly, yet the literature has remained unsatisfactory and often contradictory: ‘In routine practice, how does image-guided ablation actually compare with surgery for T1a RCC?’ Single-center experiences, limited sample sizes, substantial treatment-selection bias, and short-term follow-up have shaped most existing evidence. We therefore chose a nationwide registry-based approach to evaluate the oncological outcomes across an entire public healthcare system.
The study included 1,862 Danish adults diagnosed with biopsy-confirmed T1a RCC between 2013 and 2021. Of these, 540 underwent tumour ablation (mainly cryoablation), 1,002 underwent surgical resections, and 320 underwent nephrectomy. The primary endpoint was disease progression, defined as either distant metastasis or biopsy-verified local recurrence. This is worth emphasizing because it captures broader oncologic outcomes rather than focusing only on local tumor control at the treated site. We chose progression rather than overall survival because T1a RCC is typically a low-malignancy disease, and the patients considered for ablation or surgery are often older, with substantial competing mortality risks. As a result, overall survival may be driven less by the renal tumour itself than by age and comorbidity, making progression a more relevant endpoint for assessing the comparative oncologic performance of these treatment strategies.
The central finding was straightforward: both ablation and surgical resection were associated with similarly low risks of developing metastatic disease. The reported hazard ratio for progression for ablation versus resection was 1.46, with no statistically significant difference. At the same time, local recurrence occurred more often after ablation than after resection or nephrectomy: 2.41% after ablation, 1.20% after resection, and 0% after nephrectomy. Taken together, these two observations are, in many ways, the most important message of the paper. Ablation does not reproduce surgery perfectly. It does, however, appear to provide comparable broader oncologic control while accepting a somewhat higher likelihood of local recurrence.
That distinction matters clinically. Too often, discussions about ablation are framed in binary terms: either it is “equivalent” to surgery, or it is not. In practice, the more relevant question is whether its trade-offs are acceptable. Our data suggest that, for selected patients with T1a RCC, they often are. A higher local recurrence rate is not trivial, but neither should it be interpreted simplistically. Local recurrence after ablation may remain amenable to repeat ablation or delayed surgery and therefore does not necessarily carry the same implications as recurrence after surgery. That makes endpoint interpretation particularly important in this field. However, the most optimal management strategy following local recurrence—regardless of treatment modality—remains unclear.
The other side of the equation is treatment burden, and here the findings were equally relevant. Patients treated with ablation had shorter hospital stays and fewer 30-day hospital contacts than those treated surgically. In an era in which many small renal tumors are detected incidentally, and many patients are older or medically complex, this is not a secondary issue. Reduced peri-procedural burden is not merely a convenience outcome; it is part of the therapeutic value proposition. Recovery time, complication risk, and healthcare utilization all influence what constitutes the right treatment for a given patient.
This is where we believe the conversation should evolve. Current guidelines remain appropriately cautious. The EAU2 recommends active surveillance or tumour ablation primarily for frail and/or comorbid patients with small renal masses, strongly recommends biopsy before ablation, and advises against routinely offering cryoablation for tumours larger than 4 cm. The AUA3 similarly emphasizes pretreatment counseling and the importance of renal mass biopsy in the ablation setting. Those recommendations reflect the reality that retrospective comparisons and heterogeneous cohorts have historically dominated the evidence base. In addition, some of the persistent caution likely reflects earlier data generated when cryoablation was predominantly performed as a laparoscopic, ultrasound-guided procedure, rather than with contemporary percutaneous, image-guided techniques. Our study does not invalidate that caution. But it does strengthen the argument that ablation should no longer be viewed solely as a necessary fallback option, but as a valid treatment option in appropriately selected patients and in experienced hands.
At the same time, our findings should not be overextended. This was an observational study, not a randomized trial. Treatment allocation was not random, and residual confounding remains unavoidable, even in a large national dataset. Tumour complexity, procedural details, and some elements of physician and patient selection are difficult to fully account for in registry-based work. In addition, the ablation cohort reflected real-world practice and therefore some heterogeneity in ablative technique. The registry design also cannot fully reconstruct treatment intent. Some patients classified as undergoing nephrectomy may initially have been planned for partial nephrectomy but converted intraoperatively, and it is similarly not possible to determine whether a subset of these patients might have been candidates for cryoablation under different clinical assumptions or local practice patterns. The study also cannot account for the expertise required to deliver high-quality ablative care. As with surgery, these outcomes depend not only on the treatment modality itself but also on training, experience, multidisciplinary collaboration, and dedicated operators. The results should therefore be interpreted within the context of an established clinical infrastructure and should not be assumed to transfer automatically to any radiology department simply because cryoablation equipment is available. These are important limitations, and they should temper any attempt to turn the results into an overly broad clinical directive.
Still, real-world evidence has particular value here. One of the advantages of this study is precisely that it was not a single-center excellence report. It reflects what happens when patients are treated across a national public healthcare system in routine clinical practice. That degree of external validity is essential if we want to understand where ablation fits in everyday multidisciplinary care rather than in idealized procedural settings alone.
There is also a broader biological context to these data. The increasing incidence of small renal masses is driven largely by imaging, not necessarily by a sudden increase in clinically threatening disease.1 That has intensified interest in treatment de-escalation, active surveillance, and nephron-sparing strategies. Thus, the ongoing debate regarding the role of initial active surveillance remains a key consideration in the management of many patients and remains an area in need of further clarification. In this context, a minimally invasive treatment that appears to preserve acceptable oncologic outcomes while reducing short-term morbidity deserves serious attention. The goal is not to replace surgery indiscriminately. The goal is to better match treatment intensity to tumour biology, comorbidities, and patient preferences.
For the practicing urologist, radiologist, and multidisciplinary kidney cancer team, the practical implication is subtle but important. Surgery remains a standard. But “standard” should not mean “default without discussion.” For appropriately selected patients with T1a RCC, particularly when renal preservation, recovery, or procedural burden are major considerations, ablation can now be discussed not simply as a compromise, but as a reasonable therapeutic strategy with credible long-term support.
In that sense, the most important shift may be conceptual. The question is no longer whether ablation has a role in T1a RCC. It clearly does. The question is how confidently we are prepared to incorporate it into front-line shared decision-making. In our opinion, the answer should now be: more confidently than before, but still with careful patient selection, biopsy confirmation, and honest counseling regarding local recurrence risk.
Written by: Tommy Kjærgaard Nielsen,1,2 Anna Krarup Keller,3,4 Iben Lyskjær,4,5
- Department of Renal Surgery and Urology, Aalborg University Hospital, Aalborg, Denmark
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
- Department of Urology, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Faculty of Health, Aarhus University
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
- Ahrenfeldt, J. et al., 2025. Trends in kidney cancer: Exploring the impact of sex and age on stage of disease, and prognosis during the past three decades in Denmark—A DaRenCa study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 43(5_suppl), pp.485–485.
- Anon, EAU Guidelines on RCC - INTRODUCTION - Uroweb. [Accessed April 7, 2026a].
- Anon, Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up (2021) - American Urological Association. [Accessed April 7, 2026b].